

IFW



PATENT

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class RCE, Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Jane A. Walker January 3, 2006
Jane A. Walker Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peyman
Serial No.: 10/631,143
Filed: July 31, 2003
Group Art Unit: 1615
Confirmation No.: 2223
Examiner: Sheikh
Title: **TREATMENT OF OCULAR DISEASE**
Attorney Ref.: PMAN-23

Cincinnati, Ohio 45202

January 3, 2006

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56 and means of complying therewith according to 37 C.F.R. §§1.97 and 1.98, the references listed on the attached form PTO-1449 are called to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application.

Applicant has the following co-pending applications disclosing use of one or more macrolides: 10/289,772, 10/667,161, and 10/752,124. The references


submitted in this IDS are or were submitted or cited in applicant's co-pending applications, and are included in the pending application to ensure compliance with applicant's duty of disclosure under 37 C.F.R. §§1.97.

The Examiner is urged to consider the cited references listed on the attached form PTO-1449, and to make an independent decision with respect to materiality.

Applicant does not believe any fee is due with this submission. However, the Examiner is authorized to charge any fee or credit any overpayment to Deposit Account No. 23-3000.


Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.


Beverly A. Lyman, Ph.D.
Reg. No. 41,961

2700 Carew Tower
441 Vine Street
Cincinnati, OH 45202
513 241-2324
513 421-7269 (facsimile)

| | | | | | | | |
|-------------------------------------------------------------------------------------------|--|------------------------------------------------------------|--|------------------------------|--|--------------------------|--|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | APPLICANT Gholam Peyman | | | |
| (37 CFR 1.98(b)) | | | | FILING DATE July 31, 2003 | | GROUP 1615 | |



| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
|-----------------------|-----|---------------|---|---|---|---|---|---|---------------|--------------------|-------|----------|-------------------------------|
| EXAMINER INITIAL | | PATENT NUMBER | | | | | | | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | A.A | 4 | 0 | 7 | 9 | 0 | 3 | 8 | 03/14/78 | Choi et al. | 260 | 47 | 03/05/76 |
| | A.B | 4 | 0 | 9 | 3 | 7 | 0 | 9 | 06/06/78 | Choi et al | 424 | 19 | 01/28/75 |
| | A.C | 4 | 1 | 3 | 1 | 6 | 4 | 8 | 12/26/78 | Choi et al | 424 | 22 | 03/02/78 |
| | A.D | 4 | 1 | 3 | 8 | 3 | 4 | 4 | 02/06/79 | Choi et al | 252 | 1 | 08/24/77 |
| | A.E | 4 | 1 | 8 | 0 | 6 | 4 | 6 | 12/25/79 | Choi et al | 528 | 153 | 03/03/78 |
| | A.F | 4 | 3 | 0 | 4 | 7 | 6 | 7 | 12/08/81 | Heller et al | 424 | 78 | 05/15/80 |
| | A.G | 4 | 9 | 4 | 6 | 9 | 3 | 1 | 08/07/90 | Heller et al | 528 | 320 | 06/14/89 |
| | A.H | 5 | 2 | 9 | 4 | 6 | 0 | 4 | 03/15/94 | Nussenblatt et al. | 514 | 11 | 12/20/89 |
| | A.I | 5 | 4 | 1 | 1 | 9 | 5 | 2 | 05/1995 | Kaswan | | | |
| | A.J | 5 | 4 | 5 | 7 | 1 | 8 | 2 | 10/10/95 | Wiederrecht et al. | 530 | 402 | 02/15/94 |
| | A.K | 5 | 7 | 7 | 0 | 6 | 0 | 7 | 06/23/98 | Honbo et al. | 514 | 302 | 07/18/94 |

| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
|----------------------------------------------------------|-----|-------------------------|---------------------|-----------------------------|-------------|----------|-------------------------|
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | A.L | JP 07010752 Abstract | 01/13/95 | JP | A61K | 31/365 | N/A |
| | A.M | JP 09315954 Abstract | 12/09/97 | JP | A61K | 9/08 | N/A |
| | A.N | WO 99/22722 | 05/14/99 | PCT | A61K | 31/00 | N/A |
| | A.O | AU 17386/88 | Unknown | AU | Unknow n | Unknown | N/A |
| | A.P | AU 20350/92 | Unknown | AU | Unknow n | Unknown | N/A |
| | A.Q | CN 1333018 | 01/30/02 | CN | A61K | 9/06 | Abstract only |

| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | |
|-----------------------------------------------------------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | A.R | Algvere et al., <u>Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD</u> , European J of Ophthalmology (1999) 9(3):217-230 |
| | A.S | Anderson et al., <u>A Role for Local Inflammation in the Formation of Drusen in the Aging Eye</u> , American Journal of Ophthalmology, Vol. 134, No. 3, September 2002., pp. 411-431 |
| | A.T | Aramant et al., <u>Retinal transplanatation</u> , Science & Medicines (2000), 7:20-29 |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

| | | | | | | | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|------------------------------|---|--------------------------|---|---|---------------------|-----------------------------|-------|----------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | | | | | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b)) | | | | APPLICANT Gholam Peyman | | | | | | | | | |
| | | | | FILING DATE July 31, 2003 | | GROUP 1615 | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | | | | | | | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | B.A | 5 | 7 | 7 | 3 | 0 | 1 | 9 | 06/30/98 | Ashton et al | 424 | 423 | 09/27/95 |
| | B.B | 5 | 9 | 5 | 2 | 3 | 7 | 1 | 09/14/99 | Baker et al. | 514 | 443 | 10/08/97 |
| | B.C | 5 | 9 | 6 | 8 | 5 | 4 | 3 | 10/19/99 | Heller et al. | 424 | 425 | 12/05/97 |
| | B.D | 6 | 0 | 0 | 4 | 5 | 6 | 5 | 12/21/99 | Chiba et al. | 424 | 278.1 | 09/23/97 |
| | B.E | 6 | 1 | 7 | 9 | 8 | 1 | 7 | 01/30/01 | Zhong | 604 | 265 | 01/28/99 |
| | B.F | 6 | 2 | 3 | 9 | 1 | 1 | 3 | 05/29/01 | Dawson et al. | 514 | 29 | 06/02/99 |
| | B.G | 6 | 2 | 3 | 8 | 7 | 9 | 9 | 05/29/01 | Opolski | 428 | 423 | 02/07/97 |
| | B.H | 6 | 2 | 5 | 8 | 8 | 5 | 6 | 07/10/01 | Chamberlain et al | 514 | 912 | 07/10/01 |
| | B.I | 6 | 3 | 0 | 6 | 4 | 2 | 2 | 10/23/01 | Batich et al | 424 | 423 | 08/03/98 |
| | B.J | 6 | 3 | 5 | 0 | 4 | 4 | 2 | 02/26/02 | Garst | 424 | 78.04 | 05/30/01 |
| | B.K | 6 | 4 | 1 | 3 | 5 | 3 | 6 | 07/02/02 | Gibson et al | 424 | 423 | 08/27/99 |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | B.L | CN 1340358 | | | | | | | 03/20/03 | CN | A61K | 38/13 | Abstract only |
| | B.M | CN 1456350 | | | | | | | 11/19/2003 | CN | A61K | 9/00 | Abstract only |
| | B.N | DE 19810655 | | | | | | | 09/16/99 | DE | A61K | 38/13 | Abstract only |
| | B.O | EP 1142566 | | | | | | | 10/10/01 | EP | A61K | 9/08 | Abstract only |
| | B.P | JP 10218787 | | | | | | | 08/18/98 | JP | A61K | 38/22 | Yes |
| | B.Q | JP 1997030966 | | | | | | | 02/04/97 | JP | A61K | 31/365 | Yes |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | | | | | | | |
| | B.R | Aron-Rosa, <u>Pulsed Nd:YAG lasers in ophthalmology</u> , Nd:YAG Laser Applications pp. 34-48 | | | | | | | | | | | |
| | B.S | Carmo et al., <u>Effect of cyclosporin A on the blood-retinal barrier permeability in streptozotocin-induced diabetes</u> , Mediators of Inflammation (2000), 9(5):243-248 | | | | | | | | | | | |
| | B.T | Chiou, <u>Topical Treatment of Ocular Hypertension, Glaucoma, Ischemic Retinopathy and Age-Related Macular Degeneration with Ophthalmic Formulation of Dopamine Antagonists</u> , U.S. Patent Publication No. US 2003/0069232, published 04/10/03 | | | | | | | | | | | |
| EXAMINER | | | | | | | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | | | | | | | |

| | | | | | | | | | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|------------------------------|---|--------------------------|----------|-----------------------------|----------|-------------------------------|-------------------------|-------|----------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | | | | | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | APPLICANT Gholam Peyman | | | | | | | | | |
| | | | | FILING DATE July 31, 2003 | | GROUP 1615 | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | | | | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | | | |
| | C.A | 6 | 4 | 3 | 6 | 9 | 0 | 6 | 08/20/02 | Or et al | 514 | 29 | 04/02/01 |
| | C.B | 6 | 4 | 4 | 0 | 9 | 4 | 2 | 08/27/02 | Or et al | 514 | 30 | 12/22/00 |
| | C.C | 6 | 4 | 6 | 2 | 0 | 7 | 1 | 10/2002 | Castillejos | | | |
| | C.D | 6 | 4 | 6 | 2 | 0 | 2 | 6 | 10/08/02 | Or et al | 514 | 30 | 02/16/01 |
| | C.E | 6 | 4 | 8 | 2 | 7 | 9 | 9 | 11/2002 | Tuse et al | | | |
| | C.F | 6 | 5 | 3 | 4 | 6 | 9 | 3 | 03/18/03 | Fischell et al. | A61F | 13/00 | 01/31/01 |
| | C.G | 6 | 5 | 9 | 6 | 2 | 9 | 6 | 07/22/03 | Nelson et al | 424 | 425 | 08/04/00 |
| | C.H | 6 | 6 | 1 | 3 | 3 | 5 | 5 | 09/02/03 | Ng et al | 424 | 462 | 05/11/01 |
| | C.I | 6 | 6 | 1 | 7 | 3 | 4 | 5 | 09/09/03 | Gregory et al | 514 | 395 | 09/12/00 |
| | C.J | 6 | 6 | 6 | 7 | 3 | 7 | 1 | 12/23/03 | Ng et al | 525 | 462 | 11/14/02 |
| | C.K | 6 | 6 | 7 | 0 | 3 | 9 | 8 | 12/2003 | Edwards et a | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | PUBLICATION DATE | | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) | | |
| | C.L | JP 2001064198 | | | | 03/13/01 | | JP | A61K | 38/22 | Yes | | |
| | C.M | WO 02/24234 | | | | 03/28/02 | | PCT | A61K | 48/00 | N/A | | |
| | C.N | WO 03/051385 | | | | 06/26/03 | | PCT | A61K | 38/13 | Abstract only | | |
| | C.O | WO 03/017990 | | | | 03/06/03 | | PCT | A61K | 31/00 | N/A | | |
| | C.P | WO 2004/096261 | | | | 11/11/24 | | PCT | A61K | 38/13 | Abstract only | | |
| | C.Q | WO 2004/043480 | | | | 05/27/04 | | PCT | A61K | 38/00 | N/A | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | | | | | | | |
| | C.R | Cicciarell et al., <u>Pharmacokinetics of subconjunctivally administered cyclosporine A. Local delivery prior to chemotherapy for retinoblastoma</u> , IOVS (3/15/2001), 42(4):S332 | | | | | | | | | | | |
| | C.S | Costantini, LC, et al., <u>Immunophilin Ligands and GDNF Enhance Neurite Branching or Elongation from Developing Dopamine Neurons in Culture</u> , Experimental Neurology 164,60-70 (2000) | | | | | | | | | | | |
| | C.T | Das et al., <u>The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa patients: Results of a long-term safety study</u> , Experimental Neurology (1999), 157:58-68 | | | | | | | | | | | |
| EXAMINER | | | | | | | | DATE CONSIDERED | | | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant. | | | | | | | | | | | | | |

| | | | | | | | | | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|------------------------------|---|--------------------------|---|---------------------|-----------------------------|----------------|----------|-------------------------------|--|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | | | | | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICANT Gholam Peyman | | | | | | | | | |
| (37 CFR 1.98(b)) (Use several sheets if necessary) | | | | FILING DATE July 31, 2003 | | GROUP 1615 | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | | | | | | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| | D.A | 6 | 6 | 7 | 3 | 8 | 0 | 7 | 01/2004 | Sakai et al | | | |
| | D.B | 6 | 7 | 1 | 3 | 0 | 8 | 1 | 03/2004 | Robinson et al | | | |
| | D.C | | | | | | | | | | | | |
| | D.D | | | | | | | | | | | | |
| | D.E | | | | | | | | | | | | |
| | D.F | | | | | | | | | | | | |
| | D.G | | | | | | | | | | | | |
| | D.H | | | | | | | | | | | | |
| | D.I | | | | | | | | | | | | |
| | D.J | | | | | | | | | | | | |
| | D.K | | | | | | | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) | |
| | D.L | WO 2005/030205 | | | | | | 04/07/05 | PCT | A61K | 31/436 | N/A | |
| | D.M | WO 2005/011813 | | | | | | 02/10/05 | PCT | A61P | 27/02 | N/A | |
| | D.N | WO 89/01772 | | | | | | 03/02/89 | PCT | A61K | 9/00 | N/A | |
| | D.O | WO 99/42104 | | | | | | 08/26/99 | PCT | A61K | 31/435 | N/A | |
| | D.P | | | | | | | | | | | | |
| | D.Q | | | | | | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | | | | | | | |
| | D.R | Del Cerro et al., <u>Histologic correlation of human neural retinal transplantation</u> , Invest. Ophthalmology & Visual Science (2000) 41(10): 3142-3148 | | | | | | | | | | | |
| | D.S | Dewey, <u>2003 PCO Update: Part 1 - How the square-edged IOL prevents posterior capsular opacification</u> , Cataract & Refractive Surgery Today, September 2003, pp. 20-22 | | | | | | | | | | | |
| | D.T | Donnenfeld et al., <u>Cyclosporine provides effective treatment for dry eye</u> , Therapeutic Updates in Ophthalmology, Special Issue, July 1999, pp. 1-3 | | | | | | | | | | | |
| EXAMINER | | | | | | | | | DATE CONSIDERED | | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | | | | | | | |

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|-------|--------------------------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICANT Gholam Peyman | | | |
| (37 CFR 1.98(b)) (Use several sheets if necessary) | | | | FILING DATE July 31, 2003 | | GROUP 1615 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | E.A | | | | | | |
| | E.B | | | | | | |
| | E.C | | | | | | |
| | E.D | | | | | | |
| | E.E | | | | | | |
| | E.F | | | | | | |
| | E.G | | | | | | |
| | E.H | | | | | | |
| | E.I | | | | | | |
| | E.J | | | | | | |
| | E.K | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | E.L | | | | | | |
| | E.M | | | | | | |
| | E.N | | | | | | |
| | E.O | | | | | | |
| | E.P | | | | | | |
| | E.Q | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | E.R | Eneydi et al., <u>Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine (CsA) and dexamethasone (DEX)</u> , Investigative Ophthalmology and Visual Science, Vol. 35, No. 4, 1994, p. 1906, and Annual Meeting of the association for Research in Vision and Ophthalmology, Sarasota, FL, USA, May 1-6, 1994 abstract | | | | | |
| | E.S | Enyedi et al., <u>An intravitreal device providing sustained release of cyclosporine and dexamethasone</u> , Current Eye Research, May 1996, Vol. 15, No. 5, pp. 549-557 | | | | | |
| | E.T | Garweg et al., <u>Therapy of Goldmann-Favre's Vitreo-Retinal Degeneration with Cyclosporin A and Bromocriptine</u> , Klinische Monatsblätter für Augenheilkunde, Vol. 199, No. 3, September 1991, pp. 199-205 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|-------|--------------------------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b)) | | | | APPLICANT Gholam Peyman | | | |
| | | | | FILING DATE July 31, 2003 | | GROUP 1615 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | F.A | | | | | | |
| | F.B | | | | | | |
| | F.C | | | | | | |
| | F.D | | | | | | |
| | F.E | | | | | | |
| | F.F | | | | | | |
| | F.G | | | | | | |
| | F.H | | | | | | |
| | F.I | | | | | | |
| | F.J | | | | | | |
| | F.K | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | F.L | | | | | | |
| | F.M | | | | | | |
| | F.N | | | | | | |
| | F.O | | | | | | |
| | F.P | | | | | | |
| | F.Q | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | F.R | Gilbard, <u>EW Interview: Electrolyte balance is key to dry-eye product's success</u> , EyeWorld, February 1999, pp. 20ff | | | | | |
| | F.S | Grisolano et al., <u>Retinal Toxicity Study of Intravitreal Cyclosporin</u> , Ophthalmic Surgery, March 1986, 17:155-156 | | | | | |
| | F.T | Hageman et al., <u>Diagnostics and Therapeutics for Macular Degeneration-Related Disorders</u> , U.S. Patent Application Publication No. US 2--2/0015957, published 02/07/02 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|-----------------------------------------------------------------------------------|--------------------------|----------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | SERIAL NO. 10/631,143 | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICANT Gholam Peyman FILING DATE July 31, 2003 GROUP 1615 | | | |
| (Use several sheets if necessary) | | | | | | | |
| (37 CFR 1.98(b)) | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | G.A | | | | | | |
| | G.B | | | | | | |
| | G.C | | | | | | |
| | G.D | | | | | | |
| | G.E | | | | | | |
| | G.F | | | | | | |
| | G.G | | | | | | |
| | G.H | | | | | | |
| | G.I | | | | | | |
| | G.J | | | | | | |
| | G.K | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | G.L | | | | | | |
| | G.M | | | | | | |
| | G.N | | | | | | |
| | G.O | | | | | | |
| | G.P | | | | | | |
| | G.Q | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | G.R | Jiang et al, <u>Corneal electroretinographic function rescued by normal retinal pigment epithelial grafts in retinal degenerative Royal College of Surgeons rats</u> , Invest. Ophthalmology & Visual Science (1994). 35(13):4300-4308 | | | | | |
| | G.S | Karacorlu et al, <u>Lack of toxicity of intravitreally administered interferon Alpha-2a</u> , Ophthalmic Surgery (1999) 23:833-835 | | | | | |
| | G.T | Keep et al, <u>Introduction: Immunosuppressants as Neuroprotective Agents, Immunosuppressant Analogs in Neuroprotection, Part I: Immunosuppressants, Neurologic Disorders, and Neuroprotection</u> , Ed. Borlongan & Sanberg, Humana Press Inc., Totowa NJ, pp.3-32 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|-------|--------------------------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | APPLICANT Gholam Peyman | | | |
| (37 CFR 1.98(b)) | | | | FILING DATE July 31, 2003 | | GROUP 1615 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | H.A | | | | | | |
| | H.B | | | | | | |
| | H.C | | | | | | |
| | H.D | | | | | | |
| | H.E | | | | | | |
| | H.F | | | | | | |
| | H.G | | | | | | |
| | H.H | | | | | | |
| | H.I | | | | | | |
| | H.J | | | | | | |
| | H.K | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | H.L | | | | | | |
| | H.M | | | | | | |
| | H.N | | | | | | |
| | H.O | | | | | | |
| | H.P | | | | | | |
| | H.Q | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | H.R | Kiryu et al., <u>In Vivo Evaluation of the Inhibitory Effects of Tacrolimus (FK506) on Leukocyte Accumulation During Retinal Ischemia Reperfusion Injury</u> , Poster Presentation 1247-B128 | | | | | |
| | H.S | Lai et al, <u>Local immunosuppression prolongs survival of RPE xenografts labeled by retroviral gene transfer</u> , IOVS (9/2000) 41(10):3134-3141 | | | | | |
| | H.T | Lallemand et al., <u>Cyclosporine A delivery to the eye: A pharmaceutical challenge</u> , European Journal of Pharmaceutics and Biopharmaceutics, 56 (2003), pp. 307-318 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|--------------------------|---------------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | SERIAL NO. 10/631,143 | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | APPLICANT Gholam Peyman | | | |
| | | | | FILING DATE July 31, 2003 | | GROUP 1615 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | I.A | | | | | | |
| | I.B | | | | | | |
| | I.C | | | | | | |
| | I.D | | | | | | |
| | I.E | | | | | | |
| | I.F | | | | | | |
| | I.G | | | | | | |
| | I.H | | | | | | |
| | I.I | | | | | | |
| | I.J | | | | | | |
| | I.K | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | I.L | | | | | | |
| | I.M | | | | | | |
| | I.N | | | | | | |
| | I.O | | | | | | |
| | I.P | | | | | | |
| | I.Q | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | I.R | Lipner, <u>Dry Eye 101: Developing etiologies and treatmetns for this widespread syndrome</u> , EyeWorld, February 1999, pp. 19ff | | | | | |
| | I.S | Lipper et al., <u>Recent therapeutic advances in dermatology</u> , JAMA, Vol, 283, No. 2, January 12, 2000, pp. 175-177 | | | | | |
| | I.T | Lopez et al., <u>Transplanted retinal pigment epithelium modifies the retinal degeneration in the RCS</u> , Invest. Ophthalmology & Visual Science (1989), 30:586-588 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|-------|--------------------------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | APPLICANT Gholam Peyman | | | |
| (37 CFR 1.98(b)) | | | | FILING DATE July 31, 2003 | | GROUP 1615 | |
| | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | J.A | | | | | | |
| | J.B | | | | | | |
| | J.C | | | | | | |
| | J.D | | | | | | |
| | J.E | | | | | | |
| | J.F | | | | | | |
| | J.G | | | | | | |
| | J.H | | | | | | |
| | J.I | | | | | | |
| | J.J | | | | | | |
| | J.K | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | J.L | | | | | | |
| | J.M | | | | | | |
| | J.N | | | | | | |
| | J.O | | | | | | |
| | J.P | | | | | | |
| | J.Q | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | J.R | Lund, et al., <u>Subretinal transplantation of genetically modified human cell lines attenuates loss of visual function in dystrophic rats</u> , PNCs (2001), 98(17): 9942-9947 | | | | | |
| | J.S | Martin DF et al., <u>Synergistic Effect of Rapamycin and Cyclosporin A in the Treatment of Experimental Autoimmune Uveoretinitis</u> , The Journal of Immunology, 1995, 154:922-927 | | | | | |
| | J.T | Nicoletti et al., <u>The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats</u> , Scandinavian Journal of Immunology (1992) 36(3):415-420 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|-------|--------------------------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | APPLICANT Gholam Peyman | | | |
| | | | | FILING DATE July 31, 2003 | | GROUP 1615 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | K.A. | | | | | | |
| | K.B. | | | | | | |
| | K.C. | | | | | | |
| | K.D. | | | | | | |
| | K.E. | | | | | | |
| | K.F. | | | | | | |
| | K.G. | | | | | | |
| | K.H. | | | | | | |
| | K.I. | | | | | | |
| | K.J. | | | | | | |
| | K.K. | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | K.L. | | | | | | |
| | K.M. | | | | | | |
| | K.N. | | | | | | |
| | K.O. | | | | | | |
| | K.P. | | | | | | |
| | K.Q. | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | K.R. | Passos et al, <u>Ocular Toxicity of Intravitreal Tacrolimus</u> , Ophthalmic Surgery and Lasers, March/April 2002, Vol. 22, No. 2, pp. 140-144 | | | | | |
| | K.S. | PCT, <u>International Search Report</u> , PCT/US03/28315, mailed 06/15/04, 6 pages | | | | | |
| | K.T. | Peyman et al., <u>Intravitreal Surgery</u> , Principles and Practice, 2nd Edition, 1994, Ppleton & Lange, Connecticut, pp. 443-452 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|-----------------------------------------------------------------------------------|-------|--------------------------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICANT Gholam Peyman FILING DATE July 31, 2003 GROUP 1615 | | | |
| (Use several sheets if necessary) | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | L.A | | | | | | |
| | L.B | | | | | | |
| | L.C | | | | | | |
| | L.D | | | | | | |
| | L.E | | | | | | |
| | L.F | | | | | | |
| | L.G | | | | | | |
| | L.H | | | | | | |
| | L.I | | | | | | |
| | L.J | | | | | | |
| | L.K | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | L.L | | | | | | |
| | L.M | | | | | | |
| | L.N | | | | | | |
| | L.O | | | | | | |
| | L.P | | | | | | |
| | L.Q | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | L.R | Peyman et al., <u>Keratitis (Noninfectious)</u> , Principles and Practice of Ophthalmology, W.B. Saunders Company, 1980, pp. 446-449 | | | | | |
| | L.S | Peyman et al., <u>Intravitreal drug therapy</u> , Japanese Journal of Ophthalmology (1989), 33(4): 392-404 | | | | | |
| | L.T | Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2004/0092435, published 05/13/04, Serial No. 10/289,772, filed 11/07/02 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|-------|--------------------------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b)) (Use several sheets if necessary) | | | | APPLICANT Gholam Peyman | | | |
| | | | | FILING DATE July 31, 2003 | | GROUP 1615 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | M.A | | | | | | |
| | M.B | | | | | | |
| | M.C | | | | | | |
| | M.D | | | | | | |
| | M.E | | | | | | |
| | M.F | | | | | | |
| | M.G | | | | | | |
| | M.H | | | | | | |
| | M.I | | | | | | |
| | M.J | | | | | | |
| | M.K | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | M.L | | | | | | |
| | M.M | | | | | | |
| | M.N | | | | | | |
| | M.O | | | | | | |
| | M.P | | | | | | |
| | M.Q | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | M.R | Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2005/0025810, published 02/03/05, Serial No. 10/631,143, filed 07/31/03 | | | | | |
| | M.S | Peyman, <u>Ocular Solutions</u> , U.S. Application Publication No. 2005/0063997, published 03/24/05, Serial No. 10/752,124, filed 01/06/04 | | | | | |
| | M.T | Peyman, <u>Ocular Solutions</u> , U.S. Application Publication No. 2005/0063996, published 03/24/05, Serial No. 10/667,161, filed 09/19/03, | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|-------|--------------------------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b)) | | | | APPLICANT Gholam Peyman | | | |
| | | | | FILING DATE July 31, 2003 | | GROUP 1615 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | N.A | | | | | | |
| | N.B | | | | | | |
| | N.C | | | | | | |
| | N.D | | | | | | |
| | N.E | | | | | | |
| | N.F | | | | | | |
| | N.G | | | | | | |
| | N.H | | | | | | |
| | N.I | | | | | | |
| | N.J | | | | | | |
| | N.K | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | N.L | | | | | | |
| | N.M | | | | | | |
| | N.N | | | | | | |
| | N.O | | | | | | |
| | N.P | | | | | | |
| | N.Q | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | N.R | Peyman, <u>Pupillary Membranes: Nd:YAG Capsulotomy</u> , Intravitreal Surgery, Norwalk CT, Appleton & Lange, 1994, pp. 253-257 | | | | | |
| | N.S | Peyman et al., <u>Implantation of a sustained-release ganciclovir implant</u> , Vitreoretinal Surgical Techniques, Martin Dunitz Ltd., 2001, Chapter 45, pp. 521-531 | | | | | |
| | N.T | Schonfield and Kirst, <u>Macrolide Antibiotics</u> , Birkhausen, Basil, Switzerland, 2002, pp. 1-36 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|-----------------------------------|-------|------------------------------|-------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. PMAN/23 | | SERIAL NO. 10/631,143 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICANT Gholam Peyman | | | |
| (37 CFR 1.98(b)) | | | | (Use several sheets if necessary) | | FILING DATE July 31, 2003 | |
| GROUP 1615 | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | O.A | | | | | | |
| | O.B | | | | | | |
| | O.C | | | | | | |
| | O.D | | | | | | |
| | O.E | | | | | | |
| | O.F | | | | | | |
| | O.G | | | | | | |
| | O.H | | | | | | |
| | O.I | | | | | | |
| | O.J | | | | | | |
| | O.K | | | | | | |
| FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
| | O.L | | | | | | |
| | O.M | | | | | | |
| | O.N | | | | | | |
| | O.O | | | | | | |
| | O.P | | | | | | |
| | O.Q | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) | | | | | | | |
| | O.R | Shen et al., <u>Combined effect of cyclosporine and sirolimus on improving the longevity of recombinant adenovirus-mediated transgene expression in the retina</u> , Archives of Ophthalmology (7/2001), 119(7): 1033-1043 | | | | | |
| | O.S | Stosic-Grujicic et al, <u>Leflunomide protects mice from multiple low dose streptozotocin (MLD-SA)-induced insulinitis and diabetes</u> , Clinical & Experimental Immunology (1999) 117(1):44-50 | | | | | |
| | O.T | Ueno, <u>Composition for Topical Administration</u> , U.S. Patent Application Publication No. US2003/0044452 published 03/06/03, Serial No. 10/187,013, filed 07/02/02 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant. | | | | | | | |

SUBSTITUTE FORM PTO-1449
(MODIFIED)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
PMAN/23

SERIAL NO.
10/631,143

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT
Gholam Peyman

FILING DATE
July 31, 2003

GROUP
1615

(37 CFR 1.98(b))

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-----|---------------|---------------|----------|-------|----------|-------------------------------|
| | P.A | | | | | | |
| | P.B | | | | | | |
| | P.C | | | | | | |
| | P.D | | | | | | |
| | P.E | | | | | | |
| | P.F | | | | | | |
| | P.G | | | | | | |
| | P.H | | | | | | |
| | P.I | | | | | | |
| | P.J | | | | | | |
| | P.K | | | | | | |

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUBCLASS | TRANSLATION (YES/NO) |
|--|-----|--------------------|---------------------|-----------------------------|-------|----------|-------------------------|
| | P.L | | | | | | |
| | P.M | | | | | | |
| | P.N | | | | | | |
| | P.O | | | | | | |
| | P.P | | | | | | |
| | P.Q | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

| | | |
|--|-----|------------------------------------------------------------------------------------------------------------------------------|
| | P.R | Wakelee-Lynch, <u>Interferon may offer first drug therapy for diabetic retinopathy</u> , Diabetes Care (1992), 15(2):300-301 |
| | P.S | Wise, <u>Handbook of Pharmaceutical Controlled Release Technology</u> , Marcel Dekker, New York, 2000 |
| | P.T | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Client/Matter: PMAN-23

WHE Docket No.: 60861

The stamp of the Patent Office hereon, may be taken as acknowledging the receipt, on the date stamped, of the following items in the captioned case:

Inventor(s): Peyman

Serial No.: 10/631,143

Filing Date: July 31, 2003

Title: TREATMENT OF OCULAR DISEASE

Conf.No.: 2223

Enclosures: Supplemental Information Disclosure Statement; copies of 41 references; Certificate of Mailing; Return postcard

Beverly A. Lyman, Esquire (126)
WOOD, HERRON & EVANS, L.L.P.

November 22, 2005